Overview
Genomtec is the creator of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. The company has developed the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which detects viruses and bacteria causing respiratory tract infections and is the only solution of its kind in Europe. Additionally, Genomtec is preparing for technology trials in Asia related to its diagnostic devices.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 3.24
- High
- PLN 3.24
- Low
- PLN 3.02
- Volume
- 15.52K
- Avg. vol.
- 23.38K
- Market cap
- PLN 51.45M
- P/E ratio
- —
- EPS
- -PLN 0.67
- Shares outstanding
- 17.06M
- 52-week
- PLN 3.00 – 3.65
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLGNMTC00017
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 2.97k | USD -546.19k | USD -559.43k |
| Q1 2026 | USD 4.32k | USD -578.61k | USD -593.19k |
| Q4 2025 | USD 1.26k | USD -777.75k | USD -804.87k |
| Q1 2025 | — | — | — |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Miron Tokarski to appear in upcoming webinar “Meeting the Challenges and Unlocking the Potential of Point-of-Care Molecular Diagnostics”
Another patent granted. Another step in building global protection of Genomtec's molecular diagnostics technology
Genomtec Secured PLN 11 Million from Share Issue to Finalize Global M&A Strategy and Commercialize Breakthrough Technologies Genomtec ID and OncoSNAAT®
Start of Genomtec Public Share Offering to Raise Funds for Finalizing M&A Process and Commercializing Genomtec ID and OncoSNAAT® Technologies
Genomtec Plans Share Issue. Funds Will Support M&A Process and Project Commercialization. Company Signed Investment Agreement with Key Shareholder.
Genomtec Prepares for Technology Tests with Potential Partners in Asia as Part of M&A Process
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-12-28. Active
32 1090 2398 0000 0001 4700 7550- 40 1090 1014 0000 0001 5592 7198
- 42 1090 2398 0000 0001 4700 7564
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
9 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Feb 26, 2021 | Transformation registered | |
| Feb 11, 2021 | Transformation registered | |
| Jan 19, 2021 | Shareholders' meeting convened | |
| Jan 19, 2021 | Transformation registered | |
| Oct 15, 2020 | Transformation registered |
Public aid
18 public aid cases recorded, with a total value of $10,391,382.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 20, 2023 | Aid for research and development projects: experimental development | $2.9M$2,897,889 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 20, 2023 | Aid for research and development projects: industrial research | $2.0M$2,011,061 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 20, 2023 | Aid for SMEs for innovation support | $91,330$91,330 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
3 projects recorded: 2 from FE lists ($119,285) and 1 Commission grant (FTS) ($55,960).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-02-01 | Wsparcie przygotowania wniosku o Eurogrant z programu EIC Accelerator | $14,356$14,356 | Program Operacyjny Inteligentny Rozwój | |
| 2019-11-01 | 885874 - Genomtectumor - microrna-based tool for non-invasive early-stage cancer diagnosis | $55,960$55,960 | 1.1.31 - Horizon 2020 | |
| 2017-12-01 | Uzyskanie międzynarodowej ochrony patentowej na wynalazek dotyczący innowacyjnego sposobu detekcji materiału genetycznego w próbce biologicznej oraz mobilnego urządzenia diagnostycznego do jego realizacji. | $104.9K$104,929 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The company is represented by each member of the management board independently.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Konrad Roman Pankiewicz (49)  | Pan konrad pankiewicz jest udziałowcem w leonarto funds scsp (3,62%) oraz w pankiewicz venture sp.k. (99,9%), która to jest udziałowcem w leonarto vc sp. z o.o. sp.k. (99,9%), która to z kolei posiada ponad (25%) udziałów w leonarto funds scpp, która posiada 1 650 620 akcji genomtec s.a. co daje 25,01% udziału w kapitale i 25,01% głosów na wza. konrad pankiewicz posiada też (100%) udziałów w leonarto vc sp. z o.o., która jest komplementariuszem w leonarto vc sp. z o.o. sp.k.; Shareholder of a joint-stock company, 5.33% |
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
GMT GenomicsS.A. | 297,136.68 USD | 100% | ||
GMT IdS.A. | 162,074.55 USD | 100% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| Bacteromicsp. z o.o. | $112,732.71 | bacteromic.com | ||
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | ||
| Xenstatssp. z o.o. | $66,774.27 | xenstats.com | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Micropurasp. z o.o. | $12,556.50 | micropura.eu | ||
| InventroS.A. | $12,176.61 | inventro.co | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-06-11 | Share capital change (1,506,463.40 PLN → 1,706,463.40 PLN) | |
| 2025-09-16 | Share capital change (1,486,712.60 PLN → 1,506,463.40 PLN) | |
| 2025-03-19 | Share capital change (1,332,457.00 PLN → 1,486,712.60 PLN) | |
| 2024-05-16 | Share capital change (1,225,788.60 PLN → 1,332,457.00 PLN) | |
| 2023-10-06 | Share capital change (1,179,554.00 PLN → 1,225,788.60 PLN) |
FAQ
Last updated: 2026-08-07